RÉSUMÉ
The field of cardiac pacing has changed rapidly in the last several years. Since the initial description of His bundle pacing targeting the conduction system, recent advances in pacing the left bundle branch and its fascicles have evolved. The field and investigators' knowledge of conduction system pacing including relevant anatomy and physiology has advanced significantly. The aim of this review is to provide a comprehensive update on recent advances in conduction system pacing.
Sujet(s)
Faisceau de His , Thérapie de resynchronisation cardiaque , Humains , Bloc de branche/thérapie , Électrocardiographie , Système de conduction du coeur , Trouble de la conduction cardiaque/thérapieRÉSUMÉ
Although conventional biventricular pacing has been shown to benefit patients with heart failure and conduction system disease, there are limitations to its therapeutic success, resulting in widely variable clinical response. Limitations of conventional biventricular pacing evolve around myocardial scar, fibrosis, and inability to effectively stimulate diseased tissue. Several observational and acute hemodynamic studies have demonstrated improved electrical resynchronization and echocardiographic response with conduction system pacing. This article provides a systematic review of conduction system pacing as a physiologic alternative to conventional CRT, which is currently undergoing rigorous investigation.
Sujet(s)
Thérapie de resynchronisation cardiaque , Défaillance cardiaque , Faisceau de His , Bloc de branche , Thérapie de resynchronisation cardiaque/méthodes , Électrocardiographie/méthodes , Système de conduction du coeur , Défaillance cardiaque/thérapie , Humains , Résultat thérapeutiqueRÉSUMÉ
BACKGROUND: Ibrutinib is a tyrosine kinase inhibitor most commonly associated with atrial fibrillation. However, additional cardiotoxicities have been identified, including accelerated hypertension. The incidence and risk factors of new or worsening hypertension following ibrutinib treatment are not as well known. METHODS: We conducted a retrospective study of 144 patients diagnosed with B cell malignancies treated with ibrutinib (n=93) versus conventional chemoimmunotherapy (n=51) and evaluated their effects on blood pressure at 1, 2, 3 and 6 months after treatment initiation. Descriptive statistics were used to compare baseline characteristics for each treatment group. Fisher's exact test was used to identify covariates significantly associated with the development of hypertension. Repeated measures analyses were conducted to analyse longitudinal blood pressure changes. RESULTS: Both treatments had similar prevalence of baseline hypertension at 63.4% and 66.7%, respectively. There were no differences between treatments by age, sex and baseline cardiac comorbidities. Both systolic and diastolic blood pressure significantly increased over time with ibrutinib compared with baseline, whereas conventional chemoimmunotherapy was not associated with significant changes in blood pressure. Baseline hypertensive status did not affect the degree of blood pressure change over time. A significant increase in systolic blood pressure (defined as more than 10 mm Hg) was noted for ibrutinib (36.6%) compared with conventional chemoimmunotherapy (7.9%) at 1 month after treatment initiation. Despite being hypertensive at follow-up, 61.2% of patients who were treated with ibrutinib did not receive adequate blood pressure management (increase or addition of blood pressure medications). Within the ibrutinib group, of patients who developed more than 20 mm Hg increase in systolic blood pressure, only 52.9% had hypertension management changes. CONCLUSIONS: Ibrutinib is associated with the development of hypertension and worsening of blood pressure. Cardiologists and oncologists must be aware of this cardiotoxicity to allow timely management of blood pressure elevations.
Sujet(s)
Hypertension artérielle , Adénine/analogues et dérivés , Pression sanguine , Humains , Hypertension artérielle/induit chimiquement , Hypertension artérielle/diagnostic , Hypertension artérielle/épidémiologie , Pipéridines/pharmacologie , Pipéridines/usage thérapeutique , Études rétrospectivesRÉSUMÉ
[Figure: see text].
Sujet(s)
Potentiels d'action , Fibrillation auriculaire/étiologie , Rythme cardiaque , Transplantation cardiaque/effets indésirables , Tachycardie supraventriculaire/étiologie , Adulte , Sujet âgé , Fibrillation auriculaire/immunologie , Fibrillation auriculaire/physiopathologie , Fibrillation auriculaire/chirurgie , Ablation par cathéter , Simulation numérique , Techniques électrophysiologiques cardiaques , Femelle , Humains , Mâle , Adulte d'âge moyen , Modèles cardiovasculaires , Études rétrospectives , Tachycardie supraventriculaire/immunologie , Tachycardie supraventriculaire/physiopathologie , Tachycardie supraventriculaire/chirurgie , Résultat thérapeutique , Jeune adulteRÉSUMÉ
Several case reports described acute and subacute decompensations that were reversed after percutaneous interatrial septal defect (ASD) closure. At least 30% of patients post MitraClip will continue to have a persistent ASD at 1 year. Few retrospective studies described various echocardiographic associations with persistent ASD but there is no conclusive evidence that it is the cause of a poor outcome. Conclusion: At this time routine closure of ASD post MitraClip is not recommended unless there is hemodynamic decompensation that cannot be explained by other factors.
Sujet(s)
Communications interauriculaires , Valve atrioventriculaire gauche , Cathétérisme cardiaque/effets indésirables , Communications interauriculaires/imagerie diagnostique , Communications interauriculaires/chirurgie , Humains , Maladie iatrogène , Valve atrioventriculaire gauche/imagerie diagnostique , Valve atrioventriculaire gauche/chirurgie , Études rétrospectives , Résultat thérapeutiqueRÉSUMÉ
In chronic systolic heart failure and conduction system disease, cardiac resynchronization therapy (CRT) is the only known non-pharmacologic heart failure therapy that improves cardiac function, functional capacity, and survival while decreasing cardiac workload and hospitalization rates. While conventional bi-ventricular pacing has been shown to benefit patients with heart failure and conduction system disease, there are limitations to its therapeutic success, resulting in widely variable clinical response. Limitations of conventional CRT evolve around myocardial scar, fibrosis, and inability to effectively simulate diseased tissue. Studies have shown endocardial stimulation in closer proximity to the specialized conduction system is more effective when compared with epicardial stimulation. Several observational and acute haemodynamic studies have demonstrated improved electrical resynchronization and echocardiographic response with conduction system pacing (CSP). Our objective is to provide a systematic review of the evolution of CRT, and an introduction to CSP as an intriguing, though experimental physiologic alternative to conventional CRT.
Sujet(s)
Thérapie de resynchronisation cardiaque , Défaillance cardiaque , Bloc de branche/thérapie , Système de conduction du coeur , Défaillance cardiaque/diagnostic , Défaillance cardiaque/thérapie , Humains , Résultat thérapeutiqueRÉSUMÉ
Although ibrutinib-associated atrial and ventricular arrhythmias have been well described, there is little information about ibrutinib's effects on other electrocardiographic parameters, particularly the QT interval. Using our database of 137 patients treated with ibrutinib, we retrospectively identified 21 patients in whom an electrocardiogram (ECG) was obtained both prior to and after ibrutinib exposure. All traditional ECG parameters as well as QT dispersion were manually measured by an electrophysiologist. Compared to baseline ECGs, post ibrutinib ECGs demonstrated QT interval shortening from 386 ms to 356 ms (P = .007), corrected QT interval shortening using Bazett's formula from 446 ms to 437 ms (P = .04), and corrected QT interval shortening using Fridericia's formula from 425 ms to 407 ms (P = .003). QT dispersion also increased post ibrutinib exposure compared to baseline (39.8 ms vs 57.3 ms, P = .002). There was no significant change in other ECG parameters. In conclusion, both the absolute and corrected QT intervals significantly shortened after ibrutinib exposure, while there was a significant increase in QT dispersion. These findings may point to a common underlying electrophysiologic mechanism of ibrutinib-associated arrhythmias.
Sujet(s)
Adénine/analogues et dérivés , Troubles du rythme cardiaque/imagerie diagnostique , Troubles du rythme cardiaque/traitement médicamenteux , Électrocardiographie/méthodes , Pipéridines/usage thérapeutique , Adénine/usage thérapeutique , Troubles du rythme cardiaque/anatomopathologie , Femelle , Études de suivi , Humains , Mâle , Adulte d'âge moyen , Pronostic , Études rétrospectivesRÉSUMÉ
There is increasing evidence that rates of atrial arrhythmias (AA), specifically atrial fibrillation and flutter are elevated in patients treated with the tyrosine kinase inhibitor, ibrutinib; however, the exact risk of ibrutinib-associated AA is not definitively established. We conducted a retrospective study of 137 patients diagnosed with B-cell malignancies treated with ibrutinib compared with 106 patients treated with chemotherapy for the same cancers in order to quantify the rates and risk of AA in a "real-world" sample of cancer patients. Fisher's exact test was used to evaluate for any statistically significant differences between groups. Logistic regression was used to generate odds ratios, adjusting for potential confounders. Incidence of AA was 14% (nâ¯=â¯17) in ibrutinib-treated patients compared with 3% (nâ¯=â¯3) in patients treated with chemotherapy (pâ¯=â¯0.009). Ibrutinib-treated patients were significantly older (mean age 67 vs 63 years, pâ¯=â¯0.003); however, there were no other significant differences in baseline characteristics. Ibrutinib use, age, hypertension, and previous use of ACE inhibitors, angiotensin receptor blocker use, ß blocker use, and aspirin use were independently associated with incident arrhythmias. In multivariable analysis, patients treated with ibrutinib were associated with a 5-fold increased risk of developing AA (odds ratioâ¯=â¯5.18, 95% confidence interval 1.42 to 18.89). In conclusion, the rates and risk of AA are higher in patients treated with ibrutinib compared with chemotherapy, and this study provides strong evidence that ibrutinib itself is an independent risk factor for the development of incident AA.